Literature DB >> 25940924

ACE2-angiotensin-(1-7)-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension.

Hailong Dai1, Lihong Jiang2, Zhicheng Xiao3, Xuefeng Guang1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25940924     DOI： 10.1038/nrcardio.2015.6-c1

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  13 in total

Review 1.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

2.  ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats.

Authors:  Gang Li; Yinglong Liu; Yaobin Zhu; Aijun Liu; Yulin Xu; Xiaofeng Li; Zhiqiang Li; Junwu Su; Lizhong Sun
Journal:  Lung       Date:  2013-05-08       Impact factor: 2.584

3.  Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia.

Authors:  Axel Kleinsasser; Iris Pircher; Benedict Treml; Martin Schwienbacher; Manfred Schuster; Eveline Janzek; Hans Loibner; Josef M Penninger; Alex Loeckinger
Journal:  Wilderness Environ Med       Date:  2012-03       Impact factor: 1.518

4.  Decreased levels of serum Angiotensin-(1-7) in patients with pulmonary arterial hypertension due to congenital heart disease.

Authors:  Hailong Dai; Yongfei Gong; Zhicheng Xiao; Xuefeng Guang; Xiaolong Yin
Journal:  Int J Cardiol       Date:  2014-08-08       Impact factor: 4.164

5.  Another reason to eat your greens: cardiopulmonary protection by dietary delivery of angiotensin-converting enzyme-2 and angiotensin-(1-7) made in plants.

Authors:  Justin L Grobe; Curt D Sigmund
Journal:  Hypertension       Date:  2014-09-15       Impact factor: 10.190

6.  Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels.

Authors:  Gang Li; Yu-lin Xu; Feng Ling; Ai-jun Liu; Dong Wang; Qiang Wang; Ying-long Liu
Journal:  Chin Med J (Engl)       Date:  2012-04       Impact factor: 2.628

7.  The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease.

Authors:  Hai-long Dai; Yue Guo; Xue-feng Guang; Zhi-cheng Xiao; Ming Zhang; Xiao-long Yin
Journal:  Cardiology       Date:  2013-03-20       Impact factor: 1.869

8.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.

Authors:  Vinayak Shenoy; Anderson J Ferreira; Yanfei Qi; Rodrigo A Fraga-Silva; Carlos Díez-Freire; Autumn Dooies; Joo Yun Jun; Srinivas Sriramula; Nithya Mariappan; Dorna Pourang; Changaram S Venugopal; Joseph Francis; Timothy Reudelhuber; Robson A Santos; Jawaharlal M Patel; Mohan K Raizada; Michael J Katovich
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

9.  Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension.

Authors:  Benoît Rondelet; François Kerbaul; Ronald Van Beneden; Ives Hubloue; Sandrine Huez; Pierre Fesler; Myriam Remmelink; Serge Brimioulle; Isabelle Salmon; Robert Naeije
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-15       Impact factor: 4.733

10.  Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models.

Authors:  Vinayak Shenoy; Altin Gjymishka; Yagna P Jarajapu; Yanfei Qi; Aqeela Afzal; Katya Rigatto; Anderson J Ferreira; Rodrigo A Fraga-Silva; Patrick Kearns; Jane Yellowlees Douglas; Deepmala Agarwal; Kamal K Mubarak; Chastity Bradford; William R Kennedy; Joo Y Jun; Anandharajan Rathinasabapathy; Erin Bruce; Dipankar Gupta; Arturo J Cardounel; J Mocco; Jawaharlal M Patel; Joseph Francis; Maria B Grant; Michael J Katovich; Mohan K Raizada
Journal:  Am J Respir Crit Care Med       Date:  2013-01-31       Impact factor: 21.405
View more
  10 in total

Review 1.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

2.  Alteration in angiotensin-converting enzyme 2 by PM1 during the development of emphysema in rats.

Authors:  Hsiao-Chi Chuang; Yi-Ying Chen; Ta-Chih Hsiao; Hsiu-Chu Chou; Han-Pin Kuo; Po-Hao Feng; Shu-Chuan Ho; Jen-Kun Chen; Kai-Jen Chuang; Kang-Yun Lee
Journal:  ERJ Open Res       Date:  2020-10-05

3.  Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat.

Authors:  Eva Malikova; Kristina Galkova; Peter Vavrinec; Diana Vavrincova-Yaghi; Zuzana Kmecova; Peter Krenek; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2016-06-25       Impact factor: 3.396

4.  [Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13.

Authors:  Peiran Yang; Rhoda E Kuc; Aimée L Brame; Alex Dyson; Mervyn Singer; Robert C Glen; Joseph Cheriyan; Ian B Wilkinson; Anthony P Davenport; Janet J Maguire
Journal:  Front Neurosci       Date:  2017-02-28       Impact factor: 4.677

5.  Reversal of Hypoxic Pulmonary Hypertension by Hypoxia-Inducible Overexpression of Angiotensin-(1-7) in Pulmonary Endothelial Cells.

Authors:  Man-Ling Liu; Shu-Juan Xing; Xiao-Qing Liang; Ying Luo; Bo Zhang; Zhi-Chao Li; Ming-Qing Dong
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-18       Impact factor: 6.698

Review 6.  Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19.

Authors:  Rahul Kumar; Michael H Lee; Claudia Mickael; Biruk Kassa; Qadar Pasha; Rubin Tuder; Brian Graham
Journal:  ERJ Open Res       Date:  2020-12-07

Review 7.  Neuropathies and neurological dysfunction induced by coronaviruses.

Authors:  Mina Gholami; Sepideh Safari; Luis Ulloa; Majid Motaghinejad
Journal:  J Neurovirol       Date:  2021-05-13       Impact factor: 3.739

Review 8.  Renal Denervation Influences Angiotensin II Types 1 and 2 Receptors.

Authors:  Hajaralsadat Hosseini-Dastgerdi; Fatemeh Kharazmi; Ali-Asghar Pourshanazari; Mehdi Nematbakhsh
Journal:  Int J Nephrol       Date:  2022-10-10

9.  Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans.

Authors:  Duuamene Nyimanu; Richard G Kay; Petra Sulentic; Rhoda E Kuc; Philip Ambery; Lutz Jermutus; Frank Reimann; Fiona M Gribble; Joseph Cheriyan; Janet J Maguire; Anthony P Davenport
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

10.  The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.

Authors:  I-Chen Chen; Jao-Yu Lin; Yi-Ching Liu; Chee-Yin Chai; Jwu-Lai Yeh; Jong-Hau Hsu; Bin-Nan Wu; Zen-Kong Dai
Journal:  Int J Med Sci       Date:  2020-09-16       Impact factor: 3.738
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.